ArticleCancer medicine2026
Pan-Cancer Analysis of the Immunomodulatory Roles and Prognostic Value of PDXP and Experimental Verification in SKCM.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Multiple public databases, including TCGA, GEO, and TARGET, were utilized to comprehensively analyze pyridoxal phosphatase (PDXP) expression profiles across 34 cancer types. We further explored the associations of PDXP expression with clinicopathological features, tumor immune microenvironment, genomic heterogeneity, functional signaling pathways, and therapeutic response. In addition, in vitro and in vivo experiments were performed to preliminarily validate the potential mechanism linking PDXP expression to melanoma progression. PDXP exhibited aberrant differential expression in most cancer types and tended to be highly expressed in malignant tumor cells. PDXP expression was correlated with overall survival outcomes in 14 cancer types. In most investigated tumors, PDXP expression was significantly associated with the expression of immunoregulatory and immune checkpoint genes, as well as the general landscape of the tumor immune microenvironment. Correlation analysis of genomic characteristics indicated that PDXP may serve as a potential immune-related biomarker in skin cutaneous melanoma (SKCM). Functional enrichment and signaling pathway analysis showed that elevated PDXP expression in SKCM was correlated with enhanced tumor cell proliferative activity. In vitro and in vivo functional experiments demonstrated that PDXP knockdown significantly suppressed colony formation and migration of melanoma cells, induced G2/M phase cell cycle arrest, and increased cell apoptosis. These findings suggest that PDXP is associated with malignant phenotypes of melanoma cells, which are accompanied by changes in protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling activity. Moreover, we established a prognostic model with moderate predictive performance for melanoma using least absolute shrinkage and selection operator (LASSO)-Cox regression, providing a preliminary prognostic reference for SKCM patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.